EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

November 17, 2024

Our Impact

Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

3 days ago

Adding the immune-boosting drug Tecentriq (atezolizumab) to Herceptin (trastuzumab) plus chemotherapy showed promise in a trial in patients with ERBB2–positive gastric cancer. Via Cancer Network. ... See MoreSee Less

Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer

www.cancernetwork.com

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

7 days ago

The detection of gastric cancer in its earliest stages, when the probability of treatment success is highest, has increased by more than 50% in the last 20 years. Here’s more on this positive trend, via Healio. ... See MoreSee Less

Gastric cancer is increasingly diagnosed at early, more treatable stages

www.healio.com

SAN DIEGO — Detection of early-stage gastric cancer has become more common over the past 2 decades, while diagnosis of advanced-stage disease has been steadily declining, according to data presented...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

GI Cancers Alliance & Test Your Biomarkers recently partnered with OncLive for a series of videos on the latest updates in gastric cancer biomarker and drug development. Watch the series with Dr. Sunnie Kim at the link. ... See MoreSee Less

www.facebook.com

www.facebook.com

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

Why is stomach cancer on the rise in young adults, especially women? And what can people do to minimize their risk? City of Hope oncologist Yanghee Woo weighs in on those questions. ... See MoreSee Less

Stomach Cancer on the Rise in Young Adults, Especially Women

www.cityofhope.org

The rates of stomach cancer in young adults have been rising in the United States. Learn what the data say and how to look for potential symptoms

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

A combination of paclitaxel administered to the peritoneal cavity and standard IV-administered paclitaxel plus S-1 significantly extended survival in gastric cancer patients whose cancer had spread to the peritoneum, according to a study presented at American Society of Clinical Oncology GI Symposium earlier this year. ... See MoreSee Less

Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer

ascopost.com

Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peri...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X